


# WHAT IS MISIGHT® 1 DAY?

MiSight® 1 day is the first and only FDA-approved\* daily disposable soft contact lens proven to slow the progression of myopia in children, aged 8-12 at initiation of treatment.<sup>1†‡</sup>

## MISIGHT® 1 DAY CONTACTS DO TWO THINGS

MiSight® 1 day both corrects vision *and* slows the progression of myopia. It is a single use lens: a safe and convenient way to wear contact lenses.<sup>1,2,8,9</sup>



By including both vision correction and treatment zones in the lens, it simultaneously corrects your child's vision today, while signaling the eye to resist getting longer, with the goal of **preserving vision for the future.**<sup>1,2,8,9</sup>

## How effective is MiSight® 1 day?

In the pivotal clinical trial, MiSight® 1 day contact lens slowed the progression of myopia in age-appropriate children by 59% on average, slowed axial length elongation by 52% on average, and 41% of eyes had no progression<sup>1\*</sup>

Age-appropriate children wearing MiSight® 1 day contact lens progressed less than -1.00D on average over 6 years<sup>2§</sup>

Year 7 results from the international MiSight® 1 day clinical study found that the mean axial elongation showed no evidence of rebound – myopia control treatment gains were retained over 12 months after treatment ceased<sup>8,10||</sup>

\*Compared to single vision lens. -0.25D or less of change. Fitted at 8-12 years of age at initiation of treatment.

†Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

\*Only FDA approved soft contact lens designed for myopia control in the U.S.

§Fitted at 8-12 years of age at initiation of treatment.

||Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight® 1 day.

